{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:05:04Z","timestamp":1792569904605,"version":"4.5.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,6]]},"DOI":"10.1093\/jnci\/djp438","type":"journal-article","created":{"date-parts":[[2009,12,31]],"date-time":"2009-12-31T03:15:19Z","timestamp":1262229319000},"page":"26-38","source":"Crossref","is-referenced-by-count":161,"title":["Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case\u2013Control Study"],"prefix":"10.1093","volume":"102","author":[{"given":"Garnet L.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Bergan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Thornquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Scholler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"O'Briant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Drescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,1,6]]},"reference":[{"issue":"4","key":"key\n\t\t\t\t20170520220403_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrc1041","article-title":"The case for early detection","volume":"3","author":"Etzioni","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"key\n\t\t\t\t20170520220403_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"key\n\t\t\t\t20170520220403_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4757-3587-1_3","article-title":"Early detection of ovarian cancer: promise and reality","volume":"107","author":"Bast","year":"2002","journal-title":"Cancer Treat Res."},{"key":"key\n\t\t\t\t20170520220403_bib4","first-page":"233","article-title":"Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare","volume":"155","author":"Bast","year":"2004","journal-title":"Trans Am Clin Climatol Assoc."},{"issue":"5","key":"key\n\t\t\t\t20170520220403_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ijc.2910420507","article-title":"Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance to early detection of ovarian cancer","volume":"42","author":"Zurawski","year":"1988","journal-title":"Int J Cancer"},{"issue":"1","key":"key\n\t\t\t\t20170520220403_bib6","first-page":"14","article-title":"Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer","volume":"80","author":"Einhorn","year":"1992","journal-title":"Obstet Gynecol"},{"issue":"2","key":"key\n\t\t\t\t20170520220403_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1525-1438.1996.06020156.x","article-title":"Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer","volume":"6","author":"Woolas","year":"1996","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 10","key":"key\n\t\t\t\t20170520220403_bib8","doi-asserted-by":"crossref","first-page":"206S","DOI":"10.1200\/JCO.2003.02.955","article-title":"Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women","volume":"21","author":"Skates","year":"2003","journal-title":"J Clin Oncol"},{"issue":"14","key":"key\n\t\t\t\t20170520220403_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","article-title":"Phases of biomarker development for early detection of cancer","volume":"93","author":"Pepe","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"key\n\t\t\t\t20170520220403_bib10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0197-2456(93)90228-6","article-title":"Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET)","volume":"14","author":"Thornquist","year":"1993","journal-title":"Control Clin Trials"},{"issue":"3","key":"key\n\t\t\t\t20170520220403_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.0006-341X.2002.00657.x","article-title":"Combining several screening tests: optimality of the risk score","volume":"58","author":"McIntosh","year":"2002","journal-title":"Biometrics"},{"issue":"1","key":"key\n\t\t\t\t20170520220403_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biostatistics\/4.1.27","article-title":"A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker","volume":"4","author":"McIntosh","year":"2003","journal-title":"Biostatistics"},{"issue":"14","key":"key\n\t\t\t\t20170520220403_bib13","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/0959-8049(94)00356-A","article-title":"Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease","volume":"30A","author":"Berruti","year":"1994","journal-title":"Eur J Cancer"},{"issue":"4","key":"key\n\t\t\t\t20170520220403_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000050620","article-title":"Elevated CA125 in breast cancer\u2014a sign of advanced disease","volume":"22","author":"Norum","year":"2001","journal-title":"Tumour Biol."},{"issue":"18","key":"key\n\t\t\t\t20170520220403_bib15","first-page":"531","article-title":"Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma","volume":"23","author":"Hedman","year":"2003","journal-title":"Anticancer Res."},{"issue":"10","key":"key\n\t\t\t\t20170520220403_bib16","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1080\/1042819031000104079","article-title":"Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma","volume":"44","author":"Bairey","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"key\n\t\t\t\t20170520220403_bib17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<755::AID-CNCR27>3.0.CO;2-O","article-title":"Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity","volume":"85","author":"Burney","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"key\n\t\t\t\t20170520220403_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/088800199277137","article-title":"Serum CA 125 levels in children with non-Hodgkin's lymphoma","volume":"16","author":"Kutluk","year":"1999","journal-title":"Pediatr Hematol Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170520220403_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1634\/theoncologist.9-4-417","article-title":"Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma","volume":"9","author":"Zidan","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"key\n\t\t\t\t20170520220403_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<75::AID-CNCR11>3.0.CO;2-#","article-title":"Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement","volume":"88","author":"Camera","year":"2000","journal-title":"Cancer"},{"issue":"7","key":"key\n\t\t\t\t20170520220403_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00432-006-0189-2","article-title":"Peritoneal lavage CEA\/CA125 is a prognostic factor for gastric cancer patients","volume":"33","author":"Yamamoto","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"key\n\t\t\t\t20170520220403_bib22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/bjs.1800801220","article-title":"Raised serum CA125 level in leiomyoma and leiomyosarcoma of gastrointestinal origin","volume":"80","author":"Whiteley","year":"1993","journal-title":"Br J Surg"},{"issue":"31","key":"key\n\t\t\t\t20170520220403_bib23","doi-asserted-by":"crossref","first-page":"28619","DOI":"10.1074\/jbc.M302741200","article-title":"Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125","volume":"278","author":"Kui Wong","year":"2003","journal-title":"J Biol Chem."},{"issue":"3","key":"key\n\t\t\t\t20170520220403_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2567.2007.02660.x","article-title":"Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)","volume":"122","author":"Belisle","year":"2007","journal-title":"Immunology"},{"key":"key\n\t\t\t\t20170520220403_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/17520363.1.4.513","article-title":"CA125 in ovarian cancer","volume":"1","author":"Scholler","year":"2007","journal-title":"Biomark Med"},{"issue":"24","key":"key\n\t\t\t\t20170520220403_bib26","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.2006.09.4540","article-title":"An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy","volume":"25","author":"Liu","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"key\n\t\t\t\t20170520220403_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","article-title":"CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"16","key":"key\n\t\t\t\t20170520220403_bib28","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1158\/0008-5472.CAN-04-0746","article-title":"Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res."},{"issue":"10","key":"key\n\t\t\t\t20170520220403_bib29","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1055-9965.EPI-08-0464","article-title":"Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer","volume":"17","author":"Bertenshaw","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"key\n\t\t\t\t20170520220403_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002633","article-title":"Systematic evaluation of candidate blood markers for detecting ovarian cancer","volume":"3","author":"Palmer","year":"2008","journal-title":"PLoS ONE"},{"issue":"13","key":"key\n\t\t\t\t20170520220403_bib31","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res."},{"issue":"6","key":"key\n\t\t\t\t20170520220403_bib32","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res."},{"issue":"6","key":"key\n\t\t\t\t20170520220403_bib33","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"issue":"7, pt 1","key":"key\n\t\t\t\t20170520220403_bib34","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-05-2007","article-title":"Bead-based ELISA assays for validation of ovarian cancer early detection markers","volume":"12","author":"Scholler","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"1","key":"key\n\t\t\t\t20170520220403_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"key\n\t\t\t\t20170520220403_bib36","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem."},{"issue":"1","key":"key\n\t\t\t\t20170520220403_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol Cancer"},{"issue":"27","key":"key\n\t\t\t\t20170520220403_bib38","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1021\/bi8006324","article-title":"The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins","volume":"47","author":"Paulick","year":"2008","journal-title":"Biochemistry"},{"issue":"3","key":"key\n\t\t\t\t20170520220403_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/09687860600601494","article-title":"Recent developments in the molecular, biochemical and functional characterization of GPI8 and the GPI-anchoring mechanism [review]","volume":"23","author":"Zacks","year":"2006","journal-title":"Mol Membr Biol."},{"issue":"8","key":"key\n\t\t\t\t20170520220403_bib40","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol Cell Biol."},{"issue":"20","key":"key\n\t\t\t\t20170520220403_bib41","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","article-title":"Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma","volume":"96","author":"Scholler","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"key\n\t\t\t\t20170520220403_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2004.07.039","article-title":"Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma","volume":"95","author":"McIntosh","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170520220403_bib43","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20050930","article-title":"B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma","volume":"203","author":"Kryczek","year":"2006","journal-title":"J Exp Med"},{"issue":"6712","key":"key\n\t\t\t\t20170520220403_bib44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/25387","article-title":"Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer","volume":"396","author":"Pitti","year":"1998","journal-title":"Nature"},{"issue":"1","key":"key\n\t\t\t\t20170520220403_bib45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2007.03.007","article-title":"Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer","volume":"106","author":"Simon","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1\u20132","key":"key\n\t\t\t\t20170520220403_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jim.2006.10.003","article-title":"Method for generation of in vivo biotinylated recombinant antibodies by yeast mating","volume":"317","author":"Scholler","year":"2006","journal-title":"J Immunol Methods"},{"issue":"2","key":"key\n\t\t\t\t20170520220403_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.canlet.2007.04.012","article-title":"Development and in vitro validation of anti-mesothelin biobodies that prevent CA125\/Mesothelin-dependent cell attachment","volume":"255","author":"Bergan","year":"2007","journal-title":"Cancer Lett."},{"issue":"9","key":"key\n\t\t\t\t20170520220403_bib48","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1158\/1078-0432.CCR-07-1442","article-title":"Use of yeast-secreted in vivo biotinylated recombinant antibodies (biobodies) in bead-based ELISA","volume":"14","author":"Scholler","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"368","key":"key\n\t\t\t\t20170520220403_bib49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc."},{"key":"key\n\t\t\t\t20170520220403_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198509844.001.0001","volume-title":"The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford Statistical Science Series","author":"Pepe","year":"2003"},{"key":"key\n\t\t\t\t20170520220403_bib51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables (with discussion)","volume":"34","author":"Cox","year":"1972","journal-title":"J Roy Stat Soc B"},{"issue":"1","key":"key\n\t\t\t\t20170520220403_bib52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2004.07.039","article-title":"Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma","volume":"95","author":"McIntosh","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170520220403_bib53","first-page":"159","article-title":"Generating longitudinal screening algorithms using novel biomarkers for disease","volume":"11","author":"McIntosh","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"key\n\t\t\t\t20170520220403_bib54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170520220403_bib55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/AOG.0b013e31819cda77","article-title":"Results from four rounds of ovarian cancer screening in a randomized trial","volume":"113","author":"Partridge","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"1","key":"key\n\t\t\t\t20170520220403_bib56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0090-8258(85)90015-0","article-title":"Elevation of serum CA125 prior to diagnosis of epithelial ovarian carcinoma","volume":"22","author":"Bast","year":"1985","journal-title":"Gynecol Oncol"},{"issue":"9","key":"key\n\t\t\t\t20170520220403_bib57","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jama.1993.03500090059033","article-title":"Prospective study of serum CA-125 levels as markers of ovarian cancer","volume":"269","author":"Helzlsouer","year":"1993","journal-title":"JAMA"},{"issue":"5","key":"key\n\t\t\t\t20170520220403_bib58","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1054\/bjoc.2000.1596","article-title":"Menstrual and reproductive factors in relation to ovarian cancer risk","volume":"84","author":"Titus-Ernstoff","year":"2001","journal-title":"Br J Cancer"},{"issue":"24","key":"key\n\t\t\t\t20170520220403_bib59","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"key\n\t\t\t\t20170520220403_bib60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nbt.1546","article-title":"Multi-site assessment of the precision and reproducibility of multiple reaction monitoring\u2013based measurements of proteins in plasma","volume":"27","author":"Addona","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"9","key":"key\n\t\t\t\t20170520220403_bib61","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1021\/pr070233q","article-title":"Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes","volume":"6","author":"Faca","year":"2007","journal-title":"J Proteome Res."},{"issue":"7","key":"key\n\t\t\t\t20170520220403_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000114","article-title":"The preclinical natural history of serous ovarian cancer: defining the target for early detection","volume":"6","author":"Brown","year":"2009","journal-title":"PLoS Med"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/102\/1\/26\/17310526\/djp438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T12:28:31Z","timestamp":1739708911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djp438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,6]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1,6]]},"published-print":{"date-parts":[[2010,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djp438","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1,6]]}}}